Skip to main content

Our team includes experienced clinical coders, reimbursement and HEOR analysts, and is complemented by affiliated senior reimbursement consultants from different major countries. Our analysts speak English, French, German, Italian, Spanish, Turkish, Russian and Polish. We also have on-demand access to native speakers who are specialists in healthcare systems in other key regions of Europe (Scandinavia, the Netherlands, and Eastern European countries).

Since the very beginning, MTRC’s specialty was the medical technologies sector. While most other life science consultants spend 90% of their time on pharmaceutical projects, we do not perform any pharmaceutical projects, but dedicate 100% of our time to the area of medical technologies, so that our specialization results in higher-quality services at a lower cost.

Part of our mission and core values is our cost-effective approach to providing services. We understand the budgetary challenges of the med tech industry and can therefore offer a cost-effective approach to our specialised services. Thirty six percent (36%) of our current business comes from small to medium enterprises (SMEs) – a testament to our unique and personal approach to solving our clients’ budgetary challenges. Our prices are regarded as reasonable and generally affordable for the medical device industry (both corporations and SMEs).

One of our main focuses is on producing accurate analysis and reporting, strictly according to the timelines and expectations of our client. We are accredited by the United Kingdom Accreditation Service (UKAS) as an ISO 9001:2015 certified vendor. 

col 1

col 2

Why partner with MTRC?

Be confident in the results

We are accredited by the United Kingdom Accreditation Service (UKAS) as an ISO 9001:2015 certified vendor, specialised in medical technologies market access. Unlike many of our competitors, we dedicate 100% of our time and focus to the area of medical technologies, so that our clients enjoy higher quality services at a lower cost

Avoid the hassle of working with multiple vendors

We specialize in Pan-European projects and worked in 34 countries in Europe. You can save time, effort and money by working with a single experienced vendor vs contracting several consultants individually

Spend less on consulting

We understand the budgetary challenges of the med tech industry and can therefore offer a cost-effective approach to our specialised services. Thirty-six percent (36%) of our current business comes from small to medium-sized enterprises (SMEs) – a testament to our unique and personal approach to solve your budgetary challenges

Direct access to senior leadership

Small enough to ensure significant personal attention, and large enough to address your needs, our boutique consultancy guarantees that each project enjoys the attention it deserves with direct access to our senior leaders

Make decisions and advance your business quickly

We appreciate the time-sensitive nature of market access. Being a flexible team, we are not afraid to go beyond regular working hours to meet the high expectations of our clients. For every type of project, we offer the shortest possible turnaround times

MTRC in numbers 

An extremely specialised boutique consultancy with a global impact

22
22
Full-time employees
742
742
Projects
194
194
Clients
17
17
Regular clients from the top 30 med tech companies
36%
36%
Of business comes from Small to Medium-sized Enterprises (SMEs)

News and insights

To stay up-to-date, we constantly monitor developments of reimbursement systems in Europe

Subscribe to our newsletter to get bi-weekly updates

Subscribe Subscribe Subscribe Subscribe Subscribe Subscribe

Subscribe to our newsletter to get bi-weekly updates

20 Mar 2017

Release of the European reimbursement report for TAVI

MTRC has released reimbursement report for transcatheter aortic valve implantation in 11 European countries. Report includes information about procedure coding, payment mechanisms, reimbursement tariffs and policies for TAVI.
19 Feb 2021

Robotic-assisted surgery evaluated in Scotland

In February 2021, Healthcare Improvement Scotland released a review of recently published evidence to inform the National Planning Robotic Review Group on the impact of the number of robotic-assisted procedures (gynecological, colorectal, urological) per treatment center/surgeon on the outcomes achieved and any related evidence on the learning curves for these procedures.

Why MTRC?

Be confident in the results
Work with an ISO 9001:2015 certified (by the United Kingdom Accreditation Service) vendor, specialized in med tech market access. Unlike many competitors, we dedicate 100% of our time to the area of medical technologies, which results in higher quality and lower cost of services
Avoid hassle of working with multiple vendors
We specialize in Pan-European projects and worked in 34 countries in Europe. You can save time, effort and money by working with a single experienced vendor vs contracting several consultants individually
Spend less on consulting
We understand the budget challenges of the med tech business and offer cost-effective approach to services (36% of business comes from SMEs). Large consulting companies mostly serve pharma clients and have to cover cost for a large overhead
Make decisions and advance your business quickly
We appreciate the time-sensitive nature of market access. Being a flexible team, we are not afraid to go beyond regular working hours to meet high expectations of our clients. We worked on projects (for example, in M&A due diligence) within the shortest possible timeframes of several days
Avoid hassle of working with multiple vendors
We specialize in Pan-European projects and worked in 34 countries in Europe. You can save time, effort and money by working with a single experienced vendor vs contracting several consultants individually
Direct access to senior leadership
Being a boutique consultancy, we guarantee a significant attention to every project from the most experienced experts internally

What We Do

MTRC has been providing reimbursement, health economic and evidence synthesis services to the medical device and in-vitro diagnostics industry in Europe since 2017. 

Coding, payment mechanism, reimbursement tariffs, the pathway to create or improve reimbursement situation for the technology 

Experience in 34 EU countries, Australia and Canada

Adaptations of global models to EU countries and development of de novo models

Early and full value dossiers for the med tech industry, systematic literature reviews and meta-analyses

General introductory seminars and more than 70 country-specific seminars

Subscription service with email alerts about initiated or published health technology assessments and reimbursement decisions for medical devices and IVD tests from reimbursement (EU) and HTA (global) organizations